At Doho Weight Loss Clinic, compounded semaglutide is sourced from accredited 503a compounding pharmacies known for their commitment to safety. Like any medication, it may cause side effects, but these are typically mild and tend to resolve within a few weeks.

Compounded semaglutide is not FDA-approved and does not undergo the same rigorous efficacy and safety evaluations as FDA-approved medications. It is a glucagon-like peptide-1 (GLP-1) receptor agonist that may assist with chronic weight management when combined with a reduced-calorie diet and increased physical activity. It is typically prescribed for individuals with:

• A BMI of 30 kg/m² or greater (obesity), or
• A BMI of 27 kg/m² or greater (overweight) with at least one weight-related condition (e.g., hypertension, type 2 diabetes, or dyslipidemia).

Limitations of Use:

Do not use compounded semaglutide with other semaglutide-containing products or any GLP-1 receptor agonists.

The safety and efficacy of using compounded semaglutide with other weight-loss products have not been established.

Compounded semaglutide has not been studied in individuals with a history of pancreatitis.

Note: Compounded medications are not FDA-approved and do not have the same treatment indications as FDA-approved therapies. These suggestions are provided while FDA-approved semaglutide therapies remain in shortage.

You should avoid compounded semaglutide if:

You or your family have a history of medullary thyroid carcinoma (MTC) or an endocrine condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

You have a known allergic reaction to semaglutide or its components.

How to Administer Compounded Semaglutide

Dosing Instructions: Compounded semaglutide can be taken with or without food. It is administered weekly as a subcutaneous injection using a pre-filled injector pen.

Injection Sites: Common sites include the stomach, thigh, or upper arm. Always inject on the same day each week.

Dose Adjustments: Your Doho Weight Loss Clinic nurse practitioner will guide your treatment plan, which may include gradual dose increases every four weeks.

Important: Do not alter your dosage or discontinue compounded semaglutide without consulting your healthcare provider. For questions or concerns, contact Doho Weight Loss Clinic at 888-811-8801.

Before Using Compounded Semaglutide

Learn Proper Use: Your healthcare provider should guide you on how to properly use compounded semaglutide before your first dose.

Discuss Other Medications: Inform your provider if you are taking diabetes medications, including insulin or sulfonylureas, as these can increase the risk of low blood sugar. Your provider will discuss how to monitor and manage blood sugar levels effectively.

Consider Birth Control Options: If you use oral birth control, speak with your provider before starting compounded semaglutide. The effectiveness of birth control pills may be reduced while using this medication. Your provider may recommend an alternative form of contraception for the first 4 weeks after starting compounded semaglutide and for 4 weeks after each dose increase.

Compounded Tirzepatide Safety Information

FDA Announcement on Tirzepatide Shortage
As of October 2, 2024, the FDA announced that the shortage of tirzepatide injection, a GLP-1 medication, has officially ended.

Compounded tirzepatide is a prescription injectable medication that may assist adults with obesity or overweight conditions in losing weight and maintaining weight loss. It should be used alongside a reduced-calorie diet and increased physical activity.

This medication combines GLP-1 and GIP receptor agonist activity and is typically prescribed for individuals with:

• A BMI of 30 kg/m² or greater (obesity), or
• A BMI of 27 kg/m² or greater (overweight) with at least one weight-related condition, such as hypertension, type 2 diabetes, or dyslipidemia.

Important Safety Information

Thyroid Tumor Risk Warning

In animal studies, tirzepatide caused thyroid tumors, including thyroid cancer. It is unknown whether compounded tirzepatide increases the risk of these conditions in humans. Contact your healthcare provider immediately if you notice:

• A lump or swelling in your neck
• Hoarseness
• Trouble swallowing
• Shortness of breath

Do not use compounded tirzepatide if:

• You or your family have a history of medullary thyroid carcinoma (MTC).
• You have been diagnosed with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• You have a known allergy to tirzepatide.

Compounded tirzepatide is not FDA-approved and does not undergo the same rigorous safety and efficacy reviews as FDA-approved medications.
It is formulated by specialized compounding pharmacies based on individual patient needs and physician prescriptions.

The reason compounded tirzepatide is offered in a cash-pay practice is due to the following:

• Accessibility:
  FDA-approved tirzepatide (such as Mounjaro®) may not always be covered by insurance, especially when prescribed for weight management rather than diabetes treatment. This can make the out-of-pocket cost prohibitively expensive for many patients.

• Cost-Effectiveness:
  Compounded versions provide a more affordable option for patients who might not otherwise have access to this type of treatment.

• Customization:
  Compounded medications allow for individualized dosing and formulations that may better suit a patient’s specific needs.

While compounded medications can be effective for eligible patients, it is important to consult with a healthcare professional to understand the benefits and risks.